The Cancer Dashboard for Central and Southeastern Europe Central - - PowerPoint PPT Presentation

The Cancer Dashboard for Central and Southeastern Europe

Central European Cooperative Oncology Group (CECOG)

Christoph C. Zielinski, President

Scientific achievements in cancer research

» Improved understanding of the biology of different cancers » risk factors » underlying molecular mechanisms » Advances in diagnostic procedures » genetic profiling » biomarker testing » earlier detection » Development of sophisticated treatment strategies » treatment based on individual genetic profile » Improved diagnosis and treatment » earlier detection » increased rates of cure » extension of lives » improved quality of live

CEE: Cancer-Related Issues - to be ameliorated and discussed I.

• cancer incidence rates

» risk factors associated with emergence of certain cancer types

• primary prevention
• patient care
• allocated technological and human resources
• availability, access to and reimbursement of

molecular testing

• Poor survival and high cancer-driven mortality

» more deadly cancer types » screening programs » diagnosis at later stages associated with poorer

• utcome

» fewer available treatment options » limitations in access to treatment » delays in treatment initiation » variations in lower and/delayed availability of novel treatments

CEE: Cancer-Related Issues - to be ameliorated and discussed II.

GOIA: Discussions, Plans and Aims for CEE I.

Implementation of » National prevention programs

» tobacco smoking »

• besity

» vaccinations (HBV and HPV) » alcohol consumption

» Population-based screening programs

» Breast cancer » Cervical cancer » Colorectal cancer » Prostate cancer

» National cancer control plans » Population-based cancer registries

» information regarding treatment » “clinical benefit” and “value” of treatment modalities » effectiveness, toxicity, and cost of cancer medicines

» Approval of new medicines by FDA and EMA

» Implementation of the ESMO- Magnitude of Clinical Benefit Scale into the approval process (FDA, EMA) which are based on “value” rather than statistical significance

» Reimbursement of new medicines

» decisions more rapid » inclusion of novel drugs in routine clinical practice » better access to clinicial trials » additional investments in cancer care » more organized, value-

• riented application of novel

diagnostic and treatment approaches

GOIA: Discussions, Plans and Aims for CEE II.

Appreciation of patient advocacy groups as important stakeholders

» educated regarding cancer research » involved in clinical trials development on a regional level » increasing access to clinical trials » involved in approval processes » decision-making with regard to prioritise cancer treatment reimbursement

GOIA: Discussions, Plans and Aims for CEE III.

Development of a “cancer patient pathway”

» recording and documenting treatment outcomes » joint endeavour of healthcare professionals and patient advocacy groups » Goal: implementation of national systems of comprehensive cancer care from primary prevention to palliative care

Analysis of patient paths by patient advocacy groups Social education

» attitude towards cancer » advocate that cancer is to a large part a preventable chronic disease

GOIA: Discussions, Plans and Aims for CEE IV.

A Cancer Dashboard for CEE

Monitoring Key Metrics allow

• to effectively scrutinize cancer care performance
• to identify ways to improve cancer services
• to use local data to make change happen

The Cancer Dashboard is designed to help review cancer care in CEE countries to assess and improve the quality of services.

Prevention

Educational initiatives, awareness/prevention programs for cancer risk factors » tobacco smoking »

• besity

» vaccinations (HBV and HPV) » alcohol consumption

General Initiatives

» Legislation/regulations which restrict access and exposure to harmful products and environments » Educational campaigns tailored to different audiences to raise awareness on different risk factors for cancer » Dissemination of the European Code against Cancer (IARC) in schools, workplaces, health and community centers » Celebration and appreciation of events which give visibility to cancer prevention » Introduction of explicit funding and support for cancer epidemiology, Public Health research in the field of prevention

Prevention:

Key Performance Indicators

» Number of educational initiatives/awareness programs/sustainable prevention initiatives » Changes in legislation (smoke-free public areas, advertising for high- calorie beverages/alcohol, vaccination programs) » Smoking rates in adults/selected high risk groups » Percentage of inhabitants with

• besity

» Number of patients diagnosed with diabetes type II » Number of patients diagnosed with genital warts » Number of women newly diagnosed with cervical cancer » Number of patients diagnosed with

• ropharyngeal, penile, anus, cancers

» Number of patients diagnosed with HBV/liver disease due to HBV » Number Diagnosed Stage I and II cancers one year following awareness campaign » Screening Initiatives: Number of new cancer cases with early stage cancer in 2025 – 2030 – 2035

Diagnosis:

Key Performance Indicators (KPIs)

Initiative improve imaging diagnostics

» Increase regional coverage with state-of-the art medical imaging tools » Modernization to state-of-art equipment » Increasing the number of qualified manpower » KPI: Wait time for diagnostic imaging (CT scan, MRI, bone scan)

Initiative Standardizing and implementation of molecular testing/characterization of cancer samples in the CEE

» General reimbursement of molecular testing throughout the entire CEE region » KPI: Percentage of patients with molecular testing results » KPI: Percentage of patients on individualized therapy

Systemic Treatment and Radiotherapy:

Key Performance Indicators

Initiative: Access to novel systemic treatment

» Value-oriented reimbursement processes for novel diagnostic and treatment » KPI: Number of affordable new therapies/care solutions reimbursed in 2025 – 2030 – 2035

Initiative: increase radiotherapy in the treatment of patients with cancer

» Increase number of radiotherapy machines » Modernize equipment to state-of-the- art » Increase the number of qualified manpower » KPI: Wait time for adjuvant radiation therapy from the final pathology report » KPI: Number of people living with cancer for >10 years after diagnosis in 2025 – 2030 – 2035

Treatment:

Analyses and Key Performance Indicators I.

» Foster analysis of patients’ pathways/journey by patient advocacy groups » Time between diagnosis and initial treatment, with specification of treatment modality » Percentage of patients treated on a clinical trial at any time after diagnosis » Complete synoptic pathology report according to respective national guidelines » Percentage of patients presented to a multidisciplinary tumor board at any time after diagnosis

Treatment:

Key Performance Indicators II.

Accelerate access to therapy/Improving quality of diagnosis

» Percentage of patients with documented evidence of multidisciplinary team recommendations » Percentage of patients with evidence of communication re. the treatment plan to the GP » Overall survival by stage at initial therapy for individual malignant diseases » Percentage of patients with high-grade (3 or 4) acute toxicity with cytotoxic chemotherapy

Thank you!